Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 4, 2008, Pages 172-179

  Xiao, Yonghong ^a   Lu, Y ^a   Kang, Z ^a   Hou, F ^a   Wang, S ^a   Li, T ^a   Liu, Y ^a   Xia, Y ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Antofioxacin hydrochloride; Healthy Chinese male volunteers; Multiple dose pharmacokinetics; Serum; Tolerability; Urine

Indexed keywords

ANTOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CHINESE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PROTHROMBIN TIME; QT INTERVAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URINALYSIS; VOLUNTEER;

EID: 41849104701     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46172     Document Type: Article

References (8)

1. Bambeke FV, Michot JM, Eldere JV et al. Quinolones in 2005: an update. Clin Microbiol Infect. 2005; 11: 256-280.
2. Kaitin KI. Global drug development and international harmonization: the emergence of China as a world pharmaceutical player. Drug Inform J. 1998; 32: 1187-1191.
3. Li CJ, Chen DY, Chen KX et al. Current status of drug discovery and development in China. Chin Bull Life Sci. 2004; 16: 324-329.
4. Lin HY, Shen HL. Antibiotics clinical usage in general hospital. Chin J Nosocomial. 2006; 16: 681-683.
5. Lode H, Burner K, Keppel P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis. 1998; 27: 33-39.
6. Meibohm B, Derendorf H. Pharmacokinetic/Pharmacodynamic studies in drug product development. J Pharmaceut Sci. 2002; 91: 18-31.
7. Schaefer HG, Ahr G, Kuhlmann J. Pharmacokinetic development of quinolone antibiotics. Int J Clin Pharmacol Ther. 1995; 33: 266-276.
8. Tayab ZR, Hochhaus G, Kaufmann S et al. Do intensive care patients need an individualized dosing regimen for levofloxacin? Int J Clin Pharmacol Ther. 2006; 44: 262-269.